Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8thPRNewsWire • 08/01/22
Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 08/01/22
Precigen, Inc. (PGEN) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 07/25/22
This Analyst Believes Precigen's Non-Healthcare Divesture Removes Financial OverhangBenzinga • 07/06/22
Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova GeneticsPRNewsWire • 07/05/22
Precigen to Participate in the 2022 H.C. Wainwright Global Investment ConferencePRNewsWire • 05/17/22
Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 05/02/22
Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid LeukemiaPRNewsWire • 04/04/22
PRECIGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Precigen, Inc. f/k/a Intrexon Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmBusiness Wire • 03/29/22
Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare ConferencePRNewsWire • 01/12/22
Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom FisherZacks Investment Research • 01/11/22
Precigen: A Substantially Undervalued And Differentiated Gene Therapy CompanySeeking Alpha • 01/10/22